RTW Investments’s Standard BioTools LAB Stock Holding History

RTW Investments’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,109,500	Closed	-$9.77M	–	63
2019 Q3	$9.77M	Buy	2,109,500 +32,029	+2%	+$252K	0.58%	36
2019 Q2	$25.6M	Buy	2,077,471 +146,537	+8%	+$1.87M	1.37%	23
2019 Q1	$25.7M	Buy	1,930,934 +1,046,699	+118%	+$11M	1.75%	20
2018 Q4	$7.62M	Buy	+884,235	New	+$6.89M	0.7%	32

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RTW Investments's LAB Position: Q4 2019 in Review

RTW Investments sold out of Standard BioTools (LAB) in Q4 2019, closing a stake of 2,109,500 shares — an estimated $9.77M sold.

RTW Investments first reported a position in LAB in Q4 2018 and held it in 4 quarters. The position peaked at $25.7M in Q1 2019. 99 funds tracked by Wall St. Rank hold LAB as of Q4 2019.

RTW Investments reported no remaining Standard BioTools position as of Q4 2019 after selling out during the quarter.
RTW Investments sold 2,109,500 Standard BioTools shares in Q4 2019, an estimated $9.77M.
RTW Investments first reported a position in Standard BioTools in Q4 2018 and held it in 4 quarters.
RTW Investments's Standard BioTools position peaked at $25.7M in Q1 2019.
99 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2019.

Based on RTW Investments's 13F filing for Q4 2019, filed 14 Feb 2020.